摘要 |
The present invention relates to the discovery that CCL3, through at least one of its receptors CCRl and CCR5, plays a role in the pathologies associated with myeloid neoplasms. In various embodiments, the pathologies associated with myeloid neoplasms treatable by the compositions and methods of the invention described herein include, but are not limited to, at least one of osteoclast/osteoblast imbalance, inhibition of osteoblast function, bone loss, disregulation of the hematopoietic stem cell microenvironment, abnormal hematopoietic recovery, pancytopenia, anemia, thrombocytopenia, neutropenia, bicytopenia, and erythrocytopenia. Interfering with the interaction between CCL3 and its receptors, by targeting at least one of CCL3, CCRl, CCR5, diminishes the effects of pathologies associated with myeloid neoplasms. In various embodiments, the myeloid neoplasm is a myeloproliferative disorder, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), or myelodysplasia syndrome (MDS). |
申请人 |
UNIVERSITY OF ROCHESTER;FRISCH, BENJAMIN, J.;CALVI, LAURA, M.;BECKER, MICHAEL, W. |
发明人 |
FRISCH, BENJAMIN, J.;CALVI, LAURA, M.;BECKER, MICHAEL, W. |